The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.

[1]  S. Jordan,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. , 2017, The New England journal of medicine.

[2]  V. Tesar,et al.  Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients , 2017, Kidney international.

[3]  C. Nast,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation , 2017, The New England journal of medicine.

[4]  F. Campagne,et al.  Glomerular common gamma chain confers B- and T-cell-independent protection against glomerulonephritis. , 2017, Kidney international.

[5]  L. Björck,et al.  Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity , 2015, PloS one.

[6]  Mårten Segelmark,et al.  Diagnosis and classification of Goodpasture's disease (anti-GBM). , 2014, Journal of autoimmunity.

[7]  L. Björck,et al.  Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  L. Björck,et al.  IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential , 2008, PloS one.

[9]  Ming-hui Zhao,et al.  Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  P. Åkesson,et al.  IdeS, a Highly Specific Immunoglobulin G (IgG)-Cleaving Enzyme from Streptococcus pyogenes, Is Inhibited by Specific IgG Antibodies Generated during Infection , 2006, Infection and Immunity.

[11]  J. Wieslander,et al.  The Prognostic Significance in Goodpasture’s Disease of Specificity, Titre and Affinity of Anti-Glomerular-Basement-Membrane Antibodies , 2003, Nephron Clinical Practice.

[12]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[13]  W. K. Bolton,et al.  New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity. Nonhumorally mediated glomerulonephritis in chickens. , 1984, The Journal of clinical investigation.

[14]  C. Pusey,et al.  Treatment and prognosis in antibasement membrane antibody-mediated nephritis. , 1982, Transplantation proceedings.

[15]  T. Pearson,et al.  IMMUNOSUPPRESSION AND PLASMA-EXCHANGE IN THE TREATMENT OF GOODPASTURE'S SYNDROME , 1976, The Lancet.